{
  "id": 778,
  "text": "Although there was unanimous agreement in favour of adjuvant (chemo)radiotherapy in case of involved LN(s), parametria or surgical margin, there was debate regarding the role of adjuvant radiotherapy in case of combinations of risk factors (tumour size, deep stromal invasion, LVSI).",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: Although there was unanimous agreement in favour of adjuvant (chemo)radiotherapy in case of involved LN(s), parametria or surgical margin, there was debate regarding the role of adjuvant radiotherapy in case of combinations of risk factors (tumour size, deep stromal invasion, LVSI).\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "针对宫颈癌患者是否应该安排辅助放疗，考虑到病理因素如肿瘤大小、深基质浸润和淋巴血管间隙侵犯，在医疗界存在一些争议。这些争议主要围绕如何评估这些风险因素的组合，以及在没有淋巴结、参数侵入或手术切缘受累的情况下，辅助放疗的具体角色。\n\n一些专家认为，在肿瘤较大、深基质侵润显著、或有淋巴血管间隙侵犯等高风险因素组合情况下，辅助放疗可能有助于降低复发风险。然而，也有观点认为，对于某些患者而言，这些因素的组合可能不足以单独决定是否应用放疗，因为放疗不仅有潜在的益处，也可能带来副作用和并发症，影响患者生活质量。\n\n因此，是否安排辅助放疗通常需要考虑个体化的临床评估，结合患者具体病理特征、总体健康状况和对治疗的耐受性，并且需要与患者进行详细沟通，以做出最适合的治疗决策。这种决策通常应基于最新的临床指南、研究数据以及临床专家的经验，以确保最大化益处和最小化风险。",
  "query": "结合病理因素（肿瘤大小、深基质浸润、淋巴血管间隙侵犯）是否应该为宫颈癌患者安排辅助放疗在医疗界存在哪些争议？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 结合病理因素（肿瘤大小、深基质浸润、淋巴血管间隙侵犯）是否应该为宫颈癌患者安排辅助放疗在医疗界存在哪些争议？\n\n<reference text>: Although there was unanimous agreement in favour of adjuvant (chemo)radiotherapy in case of involved LN(s), parametria or surgical margin, there was debate regarding the role of adjuvant radiotherapy in case of combinations of risk factors (tumour size, deep stromal invasion, LVSI).\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "针对宫颈癌患者是否应该安排辅助放疗，考虑到病理因素如肿瘤大小、深基质浸润和淋巴血管间隙侵犯，在医疗界存在一些争议。这些争议主要围绕如何评估这些风险因素的组合，以及在没有淋巴结、参数侵入或手术切缘受累的情况下，辅助放疗的具体角色。\n\n一些专家认为，在肿瘤较大、深基质侵润显著、或有淋巴血管间隙侵犯等高风险因素组合情况下，辅助放疗可能有助于降低复发风险。然而，也有观点认为，对于某些患者而言，这些因素的组合可能不足以单独决定是否应用放疗，因为放疗不仅有潜在的益处，也可能带来副作用和并发症，影响患者生活质量。\n\n因此，是否安排辅助放疗通常需要考虑个体化的临床评估，结合患者具体病理特征、总体健康状况和对治疗的耐受性，并且需要与患者进行详细沟通，以做出最适合的治疗决策。这种决策通常应基于最新的临床指南、研究数据以及临床专家的经验，以确保最大化益处和最小化风险。"
}